As new drug entries shift the market for atopic dermatitis, the public onion demands changes to reimbursement assessment, such as considering the comprehensive factors to use increased treatment options efficiently.

Opinions have been suggested to consider factors related to patient quality of life, such as improving itchiness, in addition to the Eczema Area and Severity Index (EASI)-75 achievement rate, which is a typical criterion for evaluating the effectiveness of atopic dermatitis treatment.

The view is that since switching between treatments is the major focus of the guidelines for atopic dermatitis treatment revised for the first time in 9 years and focus on switching between treatmen